Johnson & Johnson agrees to acquire Ambrx Biopharma for $2bn
09 Jan 2024
License out/inADCAcquisition
Preview
Source: Pharmaceutical Technology
The acquisition of Ambrx by Johnson & Johnson is anticipated to conclude in the first half of 2024. Credit: josefkubes / Shutterstock.com.
Johnson & Johnson (J&J) has signed a definitive agreement for the acquisition of Ambrx Biopharma in a $2bn all-cash deal.
Ambrx, a clinical-stage biopharmaceutical company, is recognised for its synthetic biology platform, which is instrumental in designing and developing antibody drug conjugates (ADCs).
The company’s portfolio includes clinical and preclinical programmes that optimise the safety and efficacy of its candidate therapeutics in oncology indications.
Among the key candidates in Ambrx’s pipeline is ARX517, an ADC targeting prostate-specific membrane antigen for metastatic castration-resistant prostate cancer.
Another is ARX788, a human epidermal growth factor receptor 2 (HER2)-directed ADC for metastatic HER2-positive breast cancer.
ARX305 is also being developed to target CD-70 [cluster of differentiation 70] for renal cell carcinoma.
Researchers at J&J plan to collaborate with their Ambrx counterparts to expedite the Phase I/II APEX-01 clinical trial of ARX517 to treat advanced prostate cancer.
The companies will also progress the development of a new ADC product candidate pipeline.
The deal will be concluded in the first half of 2024.
Johnson & Johnson innovative medicine oncology global therapeutic area head Yusri Elsayed stated: “Ambrx’s ADC technology offers unique advantages in the conjugation of stable antibodies and cytotoxic linker payloads, which results in engineered ADCs that effectively kill cancer cells and limit toxicities.
“The results seen to date with ARX517 in mCRPC are promising and represent a potential first- and best-in-class targeted therapy for the treatment of this aggressive disease.
The latest development comes after the company signed a $1.7bn licensing deal with South Korean company LegoChem Biosciences to develop and market LCB84.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.